This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Panbela Therapeutics’s 8K filing here.
Panbela Therapeutics Company Profile
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Featured Stories
- Five stocks we like better than Panbela Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- Oracle Announces Game-Changing News for the AI Industry
- How to Effectively Use the MarketBeat Ratings Screener
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- Short Selling – The Pros and Cons
- Tempus AI: A Game-Changer in AI-Powered Healthcare
